alexa Phase I And Phase II Metabolites Identification Of Macrolactin A Using Human Liver Microsomes And API5500Q Trap | 10302
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

Phase I and phase II metabolites identification of macrolactin A using human liver microsomes and API5500Q trap

4th International Conference and Exhibition on Analytical & Bioanalytical Techniques

Su Min Jang, Soo Hyeon Bae, Eu Jin Choi, Jung Bae Park, Jeong Kee Lee and Soo Kyung Bae

Accepted Abstracts: J Anal Bioanal Tech

DOI: 10.4172/2155-9872.S1.015

Abstract
It was reported that macrolactin A, a polyene macrolides containing a 24-membered lactone ring, has been a bacteriostatic antibiotic that inhibits a number of multidrug-resistant gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci , and a small-colony variant of Burkholderia cepacia . Despite the excellent pharmacological properties of macrolactin A, to date there is no information regarding the Phase I or Phase II biological metabolites of macrolactin A. In our present study, we investigated and characterized the CYP and UGT enzymes that are responsible for the metabolism of MA. Furthermore, we predicted and identified the metabolic pathway of macrolactin A by lightsight software of API5500Q trap. Five different human cDNA-expressed UGTs (rUGT1A1, rUGT1A4, rUGT1A6, rUGT1A9, and rUGT2B7) and ten different human cDNA-expressed CYPs (rCYP1A2, rCYP2A6, rCYP2B6, rCYP2C8, rCYP2C9, rCYP2C19, rCYP2D6, rCYP2E1, rCYP3A4, and rCYP3A5) were used. Using human liver microsomes and human cDNA-expressed CYPs, and UGTs, we identified four phase I metabolite of macrolactin A, products of oxidation. Among these CYP isozymes, CYP3A4 and CYP3A5 are major enzymes for the formation of the metabolite of MA. Three O-glucuronide conjugations of macrolactin A also occurred. It is extensively glucuronized by mainly UGT2B7, and a lesser extent, UGT1A1, UGT1A4 and UGT1A9 and formed three different MA-glucuronides. To be specific, oxidation of MA via CYP3A4 and CYP3A5 is minor metabolic pathway of MA compared to the formation of MA-glucuronide. Taken together, MA is metabolized by UGT1A1, UGT1A4, UGT1A9, UGT2B7, and CYP3A4/5 and among these enzymes, UGT2B7 is major enzyme for the metabolism of MA.
Biography
Su Min Jang is now studying for a master?s degree in the Catholic University of Korea. The course focuses on specialization in the field of drug metabolism and pharmacokinetics.
Top